130 related articles for article (PubMed ID: 38158760)
21. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
[TBL] [Abstract][Full Text] [Related]
22. Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.
Ebrahimi A; Korshunov A; Reifenberger G; Capper D; Felsberg J; Trisolini E; Pollo B; Calatozzolo C; Prinz M; Staszewski O; Schweizer L; Schittenhelm J; Harter PN; Paulus W; Thomas C; Kohlhof-Meinecke P; Seiz-Rosenhagen M; Milde T; Casalini BM; Suwala A; Wefers AK; Reinhardt A; Sievers P; Kramm CM; Etminam N; Unterberg A; Wick W; Herold-Mende C; Sturm D; Pfister SM; Sill M; Jones DTW; Schrimpf D; Reuss DE; Aldape K; Abdullaev Z; Sahm F; von Deimling A; Stichel D
Acta Neuropathol Commun; 2022 Jan; 10(1):5. PubMed ID: 35012690
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT
Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754
[TBL] [Abstract][Full Text] [Related]
24. Molecular features of pleomorphic xanthoastrocytoma.
Zou H; Duan Y; Wei D; Zhang Y; Dai J; Li J; Li X; Zhou J; Liu Z; Jin Z; Zhang Z; Yu Y; Hu Z
Hum Pathol; 2019 Apr; 86():38-48. PubMed ID: 30496796
[TBL] [Abstract][Full Text] [Related]
25. Analysis of 24 cases of epithelioid glioblastoma: Experience from a tertiary centre of North India.
Chatterjee D; Radotra BD; Aggarwal D; Madan R; Gupta SK
Ann Diagn Pathol; 2021 Feb; 50():151679. PubMed ID: 33341703
[TBL] [Abstract][Full Text] [Related]
26. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
[TBL] [Abstract][Full Text] [Related]
27. Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.
Aisner DL; Newell KL; Pollack AG; Kleinschmidt-Demasters BK; Steinberg GK; Smyth LT; Vogel H
Clin Neuropathol; 2014; 33(2):112-21. PubMed ID: 24321241
[TBL] [Abstract][Full Text] [Related]
28. Cyclin D1 expression in ganglioglioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma.
Forest F; Dal Col P; Laville D; Court A; Rillardon M; Ramirez C; Rivoirard R; Stephan JL; Vassal F; Péoc'h M
Exp Mol Pathol; 2021 Aug; 121():104652. PubMed ID: 34022185
[TBL] [Abstract][Full Text] [Related]
29. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
Kim SH; Hwang K; Lee KS; Choe G; Kim CY
World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
[TBL] [Abstract][Full Text] [Related]
30. Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report.
Watanabe N; Ishikawa E; Kohzuki H; Sakamoto N; Zaboronok A; Matsuda M; Shibuya M; Matsumura A
BMC Neurol; 2020 Jan; 20(1):21. PubMed ID: 31941461
[TBL] [Abstract][Full Text] [Related]
31. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
[TBL] [Abstract][Full Text] [Related]
32. Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma.
Wang Y; Wang L; Blümcke I; Zhang W; Fu Y; Shan Y; Piao Y; Zhao G
Brain Pathol; 2022 Jan; 32(1):e13011. PubMed ID: 34355449
[TBL] [Abstract][Full Text] [Related]
33. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
[TBL] [Abstract][Full Text] [Related]
34. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
[TBL] [Abstract][Full Text] [Related]
35. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
[TBL] [Abstract][Full Text] [Related]
36. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
38. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
[TBL] [Abstract][Full Text] [Related]
39. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
